The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1668
ISSUE1668
January 23, 2023
Topical Roflumilast (Zoryve) for Plaque Psoriasis
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Topical Roflumilast (Zoryve) for Plaque Psoriasis
January 23, 2023 (Issue: 1668)
The FDA has approved a 0.3% cream formulation of
the phosphodiesterase-4 (PDE4) inhibitor roflumilast
(Zoryve – Arcutis) for topical treatment of plaque
psoriasis in patients ≥12 years old. Roflumilast is
the first topical PDE4 inhibitor to...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.